Upbeat 3rd-qtr for Sanofi pushes shares higher

28 October 2016

French pharma major Sanofi’s (Euronext: SAN) shares were up 7.7% before market opening, after it lifted its profit guidance for the full-year 2016 and detailing news of a big share buyback. The stock was still up 3.6% at 71.33 euros by market close on Monday.

Specifically, it said it planned to complete a 3.5 billion-euro ($3.82 billion) share buyback by the end of 2017. Sanofi also plans to divest European Union generics business, which generates about 800 million euros in annual sales, within 12-24 months

Sanofi reported a 9.7% rise in business net income to 2.3 billion euros in the third quarter, up from 2.1 billion euros a year earlier, which beat the 2 billion-euro average of 10 analyst estimates compiled by Bloomberg. Business earnings per share (EPS) were up 11.2% at 1.79 euros. Sales rose 2.1% to 9.65 billion euros, in line with analysts’ estimates.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK